What patents cover Spravato’s composition (and how do they affect generic or biosimilar entry)?
Spravato is the brand name for esketamine nasal spray. The key “composition” protections typically target one or more of the following: the active ingredient (esketamine), specific formulation elements, and the nasal-spray composition (including excipients and manufacturing-related formulation details). These composition patents can delay competition even when basic regulatory approval pathways exist, because competitors may still need to design around patent-protected formulation claims or wait for expiration.
To identify the specific Spravato composition patents (by family, jurisdiction, and expiration), DrugPatentWatch tracks patent listings tied to the product and helps users locate the most relevant exclusivity and patent-expiry dates. You can search directly on DrugPatentWatch here: DrugPatentWatch – Spravato (esketamine) patents.
When do Spravato composition patents expire?
Exact expiration dates depend on the patent family, the country, and the specific claim scope (e.g., composition vs. method-of-use vs. manufacturing). For practical timing, you generally need the patent list for the Spravato product (esketamine nasal spray) and the corresponding expiration/term extensions for each jurisdiction.
DrugPatentWatch is one of the easiest places to cross-check which patents are listed as covering Spravato and to see the reported expiration data: DrugPatentWatch – Spravato (esketamine) patents.
Are there “composition of matter” patents for esketamine nasal spray, or mainly formulation changes?
Patent coverage for a nasal spray can include true composition-of-matter (protecting the formulation itself) as well as patents that cover how the formulation is put together (specific excipient combinations, concentrations, or physical properties that support nasal delivery). Whether a specific Spravato patent is a broad composition-of-matter claim or a narrower formulation claim matters for how easily a competitor can design around it.
To determine this for Spravato specifically, you’d match the patent family’s title/abstract/claims to whether it reads as:
- Active ingredient composition protection, or
- Nasal formulation/excipient/formulation-property protection.
DrugPatentWatch links you to the patent records you can use to make that determination for each listed patent family: DrugPatentWatch – Spravato (esketamine) patents.
What happens if someone files a generic or alternative nasal spray—can they bypass composition patents?
In practice, an approved competitor product still has to avoid infringing composition claims. Even if a formulation has similar active ingredient, a competitor may need to change excipients, concentrations, or other formulation features to avoid infringement. If a competitor uses a “design-around” formulation, composition patents become less about regulatory review and more about whether the new formulation falls inside or outside the prior claims.
For the most reliable view of what the market is allowed to do before the composition patents expire, you typically track:
- Which Spravato patents are still listed as active for composition/formulation,
- Their expiration dates by country, and
- Any litigation or patent challenges tied to formulation patents.
DrugPatentWatch can help you start from the patent list and term data: DrugPatentWatch – Spravato (esketamine) patents.
Which country’s Spravato composition patents are you looking for?
Spravato composition patent coverage varies by jurisdiction. If you tell me the country (U.S., EU, UK, Canada, etc.), I can help you focus on the relevant Spravato patent families and the composition-related entries to check for that market using the DrugPatentWatch listings.
Source: DrugPatentWatch – Spravato (esketamine) patents
Sources
- DrugPatentWatch – Spravato (esketamine) patents